Sort by
Refine Your Search
-
Category
-
Country
-
Employer
- Center for Drug Evaluation and Research (CDER)
- King's College London
- National University of Singapore
- Zintellect
- Harvard University
- Nanyang Technological University
- Office of the Commissioner (OC)
- Queen's University Belfast;
- The University of Queensland
- University of Maryland, Baltimore
- University of Nottingham
- University of Oslo
- ADELAIDE UNIVERSITY
- Cardiff University
- Centre for European Policy Studies
- City of Hope
- Cori Institute of Molecular and Computational Metabolism
- DAAD
- Drexel University
- Eisbach Bio GmbH
- Ellison Institute of Technology
- IDAEA-CSIC
- Instituto de Investigação e Inovação em Saúde da Universidade do Porto (i3S)
- Life and Health Sciences Research Institute (ICVS), from the School of Medicine (EM) of the University of Minho
- Monash University
- National Center for Toxicological Research (NCTR)
- Northeastern University
- Purdue University
- QUEENS UNIVERSITY BELFAST
- SINGAPORE INSTITUTE OF TECHNOLOGY (SIT)
- The University of Alabama
- Universidade de Coimbra
- University of Alabama, Tuscaloosa
- University of Antwerp
- University of Birmingham
- University of Colorado
- University of Dundee
- University of Glasgow
- University of Michigan
- University of North Carolina at Chapel Hill
- University of Sydney
- University of Texas at Austin
- University of Washington
- Vanderbilt University
- Visterra, Inc.
- eQuest
- 36 more »
- « less
-
Field
-
) for allied health professionals, clinical psychologists, healthcare scientist, pharmacists with the General Pharmaceutical Council (GPhC) and Dentists with the General Dental Council (GDC). A3 Candidates must
-
undertaking innovative research at the intersection of biomedical engineering, pharmaceutical sciences and nanomedicine, exploring novel approaches to targeted therapeutic delivery. Through collaboration across
-
exclusive 2-year program geared toward PharmD and PhD graduates with a penchant for clinical research in the pharmaceutical and biotechnology industries. Established in 2009, the fellowship has paved
-
, business processes and supply chains, agriculture, life sciences and medicine, pharmaceuticals, and quantum systems. Underpinning these applications are fundamental principles of ethical and socially
-
doing so, EISBACH’s speerheads the development of first-in-class, next-generation precision oncology treatments. EISBACH BIO collaborates with research institutions and pharmaceutical companies to advance
-
; bioprospecting for novel microbial hosts, enzymes, and metabolites to support sustainable biomanufacturing. (Bio)pharmaceuticals: Processing science and technology for bio- and chemical transformations
-
USDA-ARS Molecular Biology Postdoctoral Fellowship in the Natural Products Utilization Research Unit
the value of crops. A secondary mission is to conduct fundamental research to aid in the development of alternative crops to produce pharmaceuticals and botanical supplement active ingredients
-
, or global health policy. By contributing to high-impact research projects spanning international regulatory operations, emerging technology, and pharmaceutical market policy, you will develop a robust
-
consumption and enhance compatibility with advanced mass spectrometry workflows. The project will target complex chemical mixtures, including wastewater-derived pollutants, pharmaceuticals, industrial chemicals
-
, including International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9/E9(R1), GCP and MHRA requirements. Evidence of methodological innovation that has informed